Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley

Morgan Stanley began coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report released on Monday morning, MarketBeat reports. The brokerage issued an overweight rating and a $29.00 price objective on the stock.

Several other research analysts have also weighed in on the stock. Royal Bank of Canada started coverage on shares of Aardvark Therapeutics in a report on Monday. They set an “outperform” rating and a $21.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of Aardvark Therapeutics in a research note on Monday. They set an “overweight” rating and a $50.00 price target on the stock. Finally, Bank of America started coverage on shares of Aardvark Therapeutics in a report on Monday. They issued a “buy” rating and a $22.00 price target on the stock.

Aardvark Therapeutics Trading Up 1.3 %

NASDAQ AARD opened at $10.26 on Monday. Aardvark Therapeutics has a twelve month low of $9.21 and a twelve month high of $19.58.

Insider Buying and Selling

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $16.00 per share, with a total value of $160,000.00. Following the transaction, the chief financial officer now owns 99,484 shares in the company, valued at approximately $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Tien-Li Lee purchased 16,542 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $16.00 per share, with a total value of $264,672.00. Following the completion of the acquisition, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. This represents a 1.12 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.